肿瘤M2型丙酮酸激酶在非小细胞肺癌疗效监测中的应用价值  

The application value of Tumor M_2-pyruvate kinase in therapeutic effect test in non-small cell lung cancer

作　　者：贾芳[1] 彭敏[1] 杨迎军[2] 张雪珂[3] 王海洋[1] 李小琳[1] 

机构地区：[1]保定市第三医院普外科,河北保定071000 [2]保定市第三医院化验室,河北保定071000 [3]保定市第三医院超声室,河北保定071000

出　　处：《临床肺科杂志》2012年第8期1467-1468,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的研究非小细胞肺癌手术前后血清肿瘤M2型丙酮酸激酶(tumor M2-PK)的应用价值。方法用酶联免疫吸附试验(ELISA)检测56例不同分期的非小细胞肺癌患者手术前后的Tu M2-PK含量的变化并进行分析。结果非小细胞肺癌患者血浆中Tu M2-PK明显高于正常人(P<0.01);非小细胞肺癌患者手术切除和不完全切除血浆中Tu M2-PK均明显低于手术前,无论手术前后,手术切除组血浆Tu M2-PK均显著低于不完全切除组(P<0.01);TNMⅢ期者明显高于Ⅰ、Ⅱ期,有淋巴结转移者显著高于无转移者(P<0.01);而非小细胞肺癌患者的性别、年龄对血浆Tu M2-PK影响无明显差别(P>0.05)。结论血浆Tu M2-PK可成为非小细胞肺癌患者病情监测及预后评估的有效指标。Objective To study the application value of Tumor M2-pyruvate kinase （Tu M2-PK） in serum before and after sur- gery in Non-small cell lung cancer. Methods Serum Tu M2-PK in 56 patients of different stages of non-small cell lung cancer before and after surgery were tested by Enzyme-linked immunosorbent assay （ELISA） and analyzed. Results Plasma Tu M2-PK in non-small cell lung cancer patients was significantly higher than normal （ P 〈 0. 01 ） ; Plasma Tu M2-PK after total resection and partial resection were sig- nificantly lower than those before surgery （ P 〈 0. 01 ）, and Plasma Tu M2-PK after total resection were significantly lower than that after partial resection（P 〈0. 01 ）. Serum Tu M2-PK in TNM Ⅲ was significantly higher than that in the stage Ⅰ ,Ⅱ and those with lymph node metastasis were significantly higher than those without metastasis（ P 〈 0. 01 ） ; Sex and age in non-small cell lung cancer patient had no effects on serum Tu M2-PK （ P 〉 0. 05 ）. Conclusion Plasma Tu M2-PK can be a effective indicator in therapeutic effect test and progno- sis evaluation in non-small cell lung cancer.

关 键 词：非小细胞肺癌 手术 肿瘤M2型丙酮酸激酶 

分 类 号：R734.2[医药卫生—肿瘤]